Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new drug heal bleeding ulcers faster? trial pits tegoprazan against lansoprazole

NCT ID NCT07708545

Disease control Sponsor: Indonesia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Aug 21, 2026 · Updated 4 times

Summary

This trial compares two medicines—tegoprazan and lansoprazole—for healing bleeding stomach ulcers. Adults with bleeding peptic ulcers receive one of the two drugs daily for 14 days, along with standard care like IV fluids and a stomach exam. A second exam after treatment checks which drug leads to better ulcer healing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tegoprazan and lansoprazole
What this could lead to
If tegoprazan works better, it could become a new standard treatment for healing bleeding stomach ulcers faster and more effectively.
What could go wrong
This is a Phase 2 trial with 162 participants, so results are preliminary. The drug may not prove superior to the existing treatment, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects aged 18 years and over. * Subjects with upper gastrointestinal bleeding caused by peptic ulcers diagnosed by gastroscopy. * Willing to participate in the entire clinical study process, including: 1. . Fluid resuscitation and blood transfusion, if necessary, 2. . High-dose PPI therapy for 72 hours, 3. . Gastroscopy within 24 hours of hospital admission and endoscopic hemostatic therapy, if necessary, 4. . Lansoprazole 30 mg or tegoprazan 50 mg therapy for 14 days, 5. . Treatment for H. pylori infection if positive, 6. . Repeat gastroscopy after 14 days of treatment to assess the progress of therapy. Exclusion Criteria: * Subjects with a history of allergy to tegoprazan or lansoprazole * Subjects with a history of allergy to tegoprazan or lansoprazole. * Subjects with ulcers caused by gastric or duodenal cancer. * Subjects with comorbidities such as chronic kidney disease stage 3 or higher and decompensated liver cirrhosis. * Patients who are heavy alcohol drinkers and have used chemotherapy drugs, bisphosphonates, or potassium supplements in the past 2 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peptic ulcer bleeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

active peptic ulcer disease peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peptic ulcer bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RSUD Balaraja

    RECRUITING

    Tangerang, Banten, 15610, Indonesia

  • RSUP Dr. M. Djamil

    RECRUITING

    Padang, West Sumatra, 25129, Indonesia

  • RSUPN Dr. Cipto Mangunkusumo

    RECRUITING

    Jakarta Pusat, DKI Jakarta, 10430, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.